Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction

127 consecutive patients with ST segment elevation myocardial infarction (STEMI), including cardiogenic shock, who underwent primary percutaneous coronary intervention. Mean age 53-59 years, 81-87% male. Single-center cohort in Turkey.

Sirolimus-eluting stents (SES) implanted during primary PCI (n=48). Standard pharmacological therapy included unfractionated heparin, aspirin (80-300 mg/d indefinitely), and clopidogrel (75 mg/d for a minimum of 6 months).

Paclitaxel-eluting stents (PES) implanted during primary PCI (n=79). Standard pharmacological therapy included unfractionated heparin, aspirin (80-300 mg/d indefinitely), and clopidogrel (75 mg/d for a minimum of 6 months).

Major adverse cardiac events (MACE), defined as a composite of death, repeat myocardial infarction (STEMI and NSTEMI), target lesion revascularization, and target vessel revascularization at 2 years follow-up.composite